<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selected studies evaluating efficacy of artemisinin combination therapies</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selected studies evaluating efficacy of artemisinin combination therapies</h1>
<div class="graphic"><div class="figure"><div class="ttl">Selected studies evaluating efficacy of artemisinin combination therapies</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1">Reference</td> <td class="subtitle1">Drug regimen</td> <td class="subtitle1">Result</td> <td class="subtitle1">Number patients</td> <td class="subtitle1">Age</td> <td class="subtitle1">Location</td> <td class="subtitle1">Year</td> </tr> <tr> <td>Ngasala BE et <span class="nowrap_whitespace">al<sup>[1]</sup></span></td> <td>Artemether-lumefantrine</td> <td>High efficacy</td> <td>359</td> <td>Children</td> <td>Tanzania</td> <td>2011</td> </tr> <tr> <td>Achan J et <span class="nowrap_whitespace">al<sup>[2]</sup></span></td> <td>Artemether-lumefantrine versus quinine</td> <td>Artemether-lumefantrine superior</td> <td>175</td> <td>Children</td> <td>Uganda</td> <td>2009</td> </tr> <tr> <td>Dorsey G et <span class="nowrap_whitespace">al<sup>[3]</sup></span></td> <td>Artemether-lumefantrine verus artesunate-amodiaquine versus amodiaquine-sulfadoxine-pyrimethamine</td> <td>Artemether-lumefantrine superior</td> <td>601</td> <td>Children</td> <td>Uganda</td> <td>2007</td> </tr> <tr> <td>Zwang J et <span class="nowrap_whitespace">al<sup>[4]</sup></span></td> <td>Artemether-lumefantrine versus artesunate-amodiaquine</td> <td>Artesunate-amodiaquine was followed by fewer recurrences</td> <td>602</td> <td>Children</td> <td>Uganda</td> <td>2016</td> </tr> <tr> <td>Toure O et <span class="nowrap_whitespace">al<sup>[5]</sup></span></td> <td>Artemether-lumefantrine versus arterolane maleate-piperaquine phosphate</td> <td>Comparable efficacy and safety</td> <td>859</td> <td>Children</td> <td>Africa and India</td> <td>2017</td> </tr> <tr> <td>Thriemer K et <span class="nowrap_whitespace">al<sup>[6]</sup></span></td> <td>Artemether-lumefantrine versus artesunate-azithromycin</td> <td>Equivalent cure rates</td> <td>228</td> <td>Adults and children</td> <td>Bangladesh</td> <td>2010</td> </tr> <tr> <td>Zwang J et <span class="nowrap_whitespace">al<sup>[7]</sup></span></td> <td>Artesunate-amodiaquine versus non-ACT therapy</td> <td>Artesunate-amodiaquine superior to non-ACT therapy</td> <td>11,700</td> <td>Adults and children</td> <td>Multi-country</td> <td>2009</td> </tr> <tr> <td>Tahar R et <span class="nowrap_whitespace">al<sup>[8]</sup></span></td> <td>Artesunate-amodiaquine versus atovaquone-proguanil versus artesunate-atovaquone-proguanil</td> <td>Equivalent efficacies by PCR; slower clearance with atovaquone-proguanil arm versus artesunate-atovaquone-proguanil</td> <td>338</td> <td>Children</td> <td>Cameroon</td> <td>2014</td> </tr> <tr> <td>Sirima S et <span class="nowrap_whitespace">al<sup>[9]</sup></span></td> <td>Artesunate-mefloquine versus artemether-lumefantrine</td> <td>Comparable efficacy with similar rates of adverse events</td> <td>945</td> <td>Children</td> <td>Burkina Faso, Kenya, and Tanzania</td> <td>2016</td> </tr> <tr> <td>Smithuis F et <span class="nowrap_whitespace">al<sup>[10]</sup></span></td> <td>Artesunate-mefloquine versus artesunate-amodiaquine versus dihydroartemisinin-piperaquine versus artemether-lumefantrine</td> <td>Artesunate-mefloquine greatest posttreatment suppression</td> <td>808</td> <td>Adults and children</td> <td>Myanmar</td> <td>2010</td> </tr> <tr> <td>Rueangweerayut R et <span class="nowrap_whitespace">al<sup>[11]</sup></span></td> <td>Artesunate-mefloquine versus pyronaridine-artesunate</td> <td>Similar efficacies; longer parasite clearance times with pyronaridine-artesunate</td> <td>1271</td> <td>Adults and children</td> <td>Multi-country</td> <td>2012</td> </tr> <tr> <td>Sagara I et <span class="nowrap_whitespace">al<sup>[12]</sup></span></td> <td>Either pyronaridine-artesunate or dihydroartemisinin-piperaquine versus either artesunate-amodiaquine or artemether-lumefantrine</td> <td>Pyronaridine-artesunate and dihydroartemisinin-piperaquine noninferior to artesunate-amodiaquine and artemether-lumefantrine</td> <td>4710</td> <td>Adults and children</td> <td>Burkina Faso, Guinea, and Mali</td> <td>2018</td> </tr> <tr> <td>Zani B et <span class="nowrap_whitespace">al<sup>[13]</sup></span></td> <td>Dihydroartemisinin-piperaquine versus other ACTs</td> <td> <p>In Africa: Dihydroartemisinin-piperaquine reduces treatment failure compared with artemether-lumefantrine, (though both with PCR-adjusted failure rates &lt;5%)</p> In Asia: Dihydroartemisinin-piperaquine as effective as artesunate-mefloquine</td> <td>16,382</td> <td>Adults and children</td> <td>Multi-country</td> <td>2014</td> </tr> <tr> <td>Wanzira H et <span class="nowrap_whitespace">al<sup>[14]</sup></span></td> <td>Dihydroartemisinin-piperaquine versus artemether-lumefantrine</td> <td>Dihydroartemisinin-piperaquine superior</td> <td>312</td> <td>Children</td> <td>Uganda</td> <td>2014</td> </tr> <tr> <td>Yeka et <span class="nowrap_whitespace">al<sup>[15]</sup></span></td> <td>Dihydroartemisinin-piperaquine artemether-lumefantrine</td> <td>Regimens equivalent for treatment of uncomplicated <em>Plasmodium falciparum</em> malaria</td> <td>599</td> <td>Children</td> <td>Uganda</td> <td>2019</td> </tr> <tr> <td>Pryce et <span class="nowrap_whitespace">al<sup>[16]</sup></span></td> <td>Pyronaridine-artesunate compared with alternative ACTs</td> <td>Pyronaridine-artesunate efficacious against uncomplicated <em>P. falciparum</em> malaria; treatment failure rate of &lt;5% at days 28 and 42; may be at least as good as or better than other ACTs</td> <td>5711</td> <td>Adults and children</td> <td>Multicountry, Africa, and Asia</td> <td>5 studies published up until October 2021</td> </tr> </tbody></table></div><div class="graphic_footnotes">ACT: artemisinin combination therapy; PCR: polymerase chain reaction.</div><div class="graphic_reference">References:
<ol>
<li>Ngasala BE, Malmberg M, Carlsson AM, et al. Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children &lt;5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. Clin Infect Dis 2011; 52:873.</li>
<li>Achan J, Tibenderana JK, Kyabayinze D, et al. Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ 2009; 339:b2763.</li>
<li>Dorsey G, Staedke S, Clark TD, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 2007; 297:2210.</li>
<li>Yeka A, Kigozi R, Conrad MD, et al. Artesunate/amodiaquine versus artemether/lumefantrine for the treatment of uncomplicated malaria in Uganda: A randomized trial. J Infect Dis 2016; 213:1134.</li>
<li>Toure OA, Mwapasa V, Sagara I, et al. Assessment of efficacy and safety of arterolane maleate-piperaquine phosphate dispersible tablets in comparison with artemether-lumefantrine dispersible tablets in pediatric patients with acute uncomplicated Plasmodium falciparum malaria: A phase 3, randomized, multicenter trial in India and Africa. Clin Infect Dis 2017; 65:1711.</li>
<li>Thriemer K, Starzengruber P, Khan WA, et al. Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial. J Infect Dis 2010; 202:392.</li>
<li>Zwang J, Olliaro P, Barennes H, et al. Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J 2009; 8:203.</li>
<li>Tahar R, Almelli T, Debue C, et al. Randomized trial of artesunate-amodiaquine, atovaquone-proguanil, and artesunate-atovaquone-proguanil for the treatment of uncomplicated falciparum malaria in children. J Infect Dis 2014; 210:1962.</li>
<li>Sirima SB, Ogutu B, Lusingu JPA, et al. Comparison of artesunate–mefloquine and artemether–lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. Lancet 2016; 16:1123.</li>
<li>Smithuis F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 2010; 10:673.</li>
<li>Rueangweerayut R, Phyo AP, Uthaisin C, et al. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Eng J Med 2012; 366:1298.</li>
<li>West African Network for Clinical Trials of Antimalarial Drugs (WANECAM). Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet 2018; 391:1378.</li>
<li>Zani B, Gathu M, Donegan S, et al. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev 2014; 1:CD010927.</li>
<li>Wanzira H, Kakuru A, Arinaitwe E, et al. Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria. Clin Infect Dis 2014; 59:509.</li>
<li>Yeka A, Wallender E, Mulebeke R, et al. Comparative efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Ugandan children. J Infect Dis 2019; 219:1112.</li>
<li>Pryce J, Taylor M, Fox T, Hine P. Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev 2022; 6:CD006404.</li>
</ol></div><div id="graphicVersion">Graphic 107437 Version 9.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
